<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312503</url>
  </required_header>
  <id_info>
    <org_study_id>151(A)PO18531</org_study_id>
    <nct_id>NCT04312503</nct_id>
  </id_info>
  <brief_title>Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia&quot;</brief_title>
  <acronym>SWITCH</acronym>
  <official_title>Observational Study on the Effect of Switch to Lurasidone or Other Antipsychothics on Metabolic and Weight Changes in Subjects With Schizophrenia&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is observation, in an Italian real-world setting, of metabolic effects
      in patients with schizophrenia who will switch from any mono-therapy or poly-therapy
      antipsychotic regimen to monotherapy with lurasidone or to one of the other four most used
      atypical antipsychotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is the observation, in psychiatric Italian real-world settings, of
      metabolic effects, effectiveness, side effects and therapeutic adherence in patients with
      schizophrenia who switched, for any reason (efficacy, safety, metabolic problems, therapeutic
      adherence or patient's request), from any mono-therapy or poly-therapy antipsychotic regimen
      to monotherapy with lurasidone or with one of the four most used atypical antipsychotics in
      Italy (aripiprazole, olanzapine, quetiapine, risperidone). Patient's past medical and
      psychiatric history of the last 12 months will be also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the metabolic parameters</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in metabolic syndrome in 3 of 5 parameters:
Arterial hypertension defined as. systolic pressure ≥ 130 mmHg and/or diastolic pressure ≥85 mmHg or treatment for hypertension.
Waist Circumference ≥ 90 cm in men or ≥ 80 cm in women.
Fasting Plasma Glucose ≥5.6 mmol/l and/or known treatment for hyperglycemia.
Triglycerides ≥1.7 mmol/l or medication for elevated triglycerides.
HDL Cholesterol ≤ 1.0 mmol/l in men and ≤1.3 mmol/l for women or taking medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retrospective investigation of the metabolic effects of switches to any atypical antipsychotic occurred in the previous 12 months</measure>
    <time_frame>12 months before baseline (switch to any atypical antipsychotics)</time_frame>
    <description>Change in metabolic syndrome in 3 of 5 parameters:
Arterial hypertension defined as. systolic pressure ≥ 130 mmHg and/or diastolic pressure ≥85 mmHg or treatment for hypertension.
Waist Circumference ≥ 90 cm in men or ≥ 80 cm in women.
Fasting Plasma Glucose ≥5.6 mmol/l and/or known treatment for hyperglycemia.
Triglycerides ≥1.7 mmol/l or medication for elevated triglycerides.
HDL Cholesterol ≤ 1.0 mmol/l in men and ≤1.3 mmol/l for women or taking medication.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>COHORT A: Lurasidone</arm_group_label>
    <description>Patients treated with Lurasidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT B: aripiprazole, olanzapine, quetiapine or risperidone)</arm_group_label>
    <description>Patients treated with other atipical antypsicothic as aripiprazole, olanzapine, quetiapine or risperidone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Patients are treated with dosages according clinical practice</description>
    <arm_group_label>COHORT A: Lurasidone</arm_group_label>
    <other_name>Latuda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aripiprazole, olanzapine, quetiapine or risperidone</intervention_name>
    <description>Patients are treated with dosages according clinical practice</description>
    <arm_group_label>COHORT B: aripiprazole, olanzapine, quetiapine or risperidone)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include adult patients (aged &gt; 18 years) affected by
        schizophrenia according to DSM-5 (Appendix A).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of schizophrenia according to DSM-5.

          -  Patients who gave their written consent for participation in the study and for
             personal data processing and willing to comply with all study procedures.

          -  Male and female patients ≥ of 18 years old at baseline.

          -  Patients treated or in treatment with any typical or atypical antipsychotic
             monotherapy or polytherapy.

          -  Patients switched from the pre-existing therapy to lurasidone, aripiprazole,
             olanzapine, quetiapine or risperidone in monotherapy within the preceding 2 weeks. The
             date of the switch is considered as baseline.

        Exclusion Criteria:

          -  Female patients who are pregnant or lactating

          -  Patients fulfilling DSM-5 criteria for diagnosis of bipolar disorder and/or dementia.

          -  Amphetamines and/or Opiates abuse or dependence , as defined by DSM-5 criteria.

          -  Patients with no history of antipsychotics use.

          -  Patients recruited in another study as follows:

          -  currently enrolled in any pharmacological or non-pharmacological, interventional or
             observational study:

          -  who participated in the last 30 days to any observational or no-profit interventional
             study;

          -  who participated in the last 12 months to any interventional commercially sponsored
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alessandro Dr Ruggieri</last_name>
    <phone>+3906910451</phone>
    <phone_ext>309</phone_ext>
    <email>alessandro.ruggieri@angelinipharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandra Dr Del Vecchio</last_name>
    <phone>39 06 910451</phone>
    <phone_ext>311</phone_ext>
    <email>alessandra.delvecchio@angelinipharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedali Riuniti SOD di Clinica Psichiatrica</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia Dipartimento di Salute Mentale 1</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Cagliari Corso Vittorio Emanuele II, 6 09124 Cagliari (CA)</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. Gaspare Rodolico - U.O.C. di Psichiatria</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Mater Domini U.O. Psichiatria</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Ospedali Riuniti di Foggia - S.P.D.C. Viale Pinto 71121 Foggia (FO)</name>
      <address>
        <city>Foggia</city>
        <state>FG</state>
        <zip>71121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DSM Dipartimento Salute Mentale</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Gerardo Università Bicocca Dipartimento di Salute Mentale</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>209900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico di Milano U.O. C. di Psichiatria</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele U.O.C. Psichiatria Generale e Riabilitazione</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco, S.C. Psichiatria 2</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III S.P.D.C. Azienda Ospedaliera di Padova 35128 Padova - (PD)</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Von Sibenthal Via della Madonnina, 1</name>
      <address>
        <city>Genzano Di Roma</city>
        <state>RM</state>
        <zip>00045</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Luigi Gonzaga - S.C.D.U. di Psichiatria Regione Gonzole, 10</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>lurasidone</keyword>
  <keyword>antipsychotics</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>switch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

